

# *Pathology & Oncology Research*

## News from POR

### Our Editors-in-Chief



József Tímár



László Kopper



Anna Sebestyén



Andrea Ladányi

Publishing clinical trials with negative end result is a very rare phenomenon, since authors and Journals used to publish new research discoveries and successful clinical trials. In this way the general audience is not informed about trials ended with negative results, however these results are important and can be clinically equally relevant. POR encourage authors/clinicians to come forward with those negative trials to help to design more successful treatment options for cancer patients. The recently published paper by E. Talor and his colleagues on the negative results of the IT-MATTERS phase-3 study on neoadjuvant immunotherapy of oral cancer is the first of such an effort. (PORE.2025.1612084)

**Prof. József Tímár**  
Editor-in-Chief

## Recently Published Articles

### Articles Selected by Our Editors-in-Chief

**Neoadjuvant Leukocyte  
Interleukin Injection  
Immunotherapy Improves  
Overall Survival in Low-  
risk Locally Advanced  
Head and Neck Squamous  
Cell Carcinoma -The IT-  
MATTERS Study**

Talor E et al

**Management  
and Surveillance  
of Metastatic  
Giant Cell  
Tumour of Bone**

Fellows D et al

**Impact of comprehensive  
genomic profiling on the  
diagnosis and clinical  
management of malignant  
mesenchymal tumours**

Csepregi AB et al

**More articles published in POR**

Participate in a forum for the latest developments in pathology and oncology, including basic research and clinical medicine!

[Learn more and submit](#)

## Our Recent Special Issues

We have 14 Special Issues open for submissions covering a wide range of topics such as cellular communication, animal and alternative disease models, oncologic imaging, innovative trial designs, and oncology of various organ systems led by teams of experts from 8 countries including:

- Zsolt Orosz, Nuffield Orthopaedic Centre in the United Kingdom.
- María Jesús Fernández Aceñero, San Carlos University Clinical Hospital in Spain
- Fabio Grizzi, Humanitas Research Hospital in Italy
- Maria Harmati, HUN-REN Biological Research Centre, in Hungary

[Learn more about our Special Issues](#)

Experts in their field of research are welcome to shape the editorial direction of POR by leading an article collection.

[Share your ideas with us](#)

## Editorial Board

Our international Editorial Board has experts in various fields of pathology and oncology, and we are always eager to hear from specialists of their fields interested in joining our community. At POR, we are particularly interested in hearing from prospective Reviewers with expertise in, but not limited to:

- Precision oncology.
- Immunoresistance of cancer.
- Tumor-agnostic therapies of cancer.

[Visit our Editorial Board](#)

Interested in joining our active community of researchers and sharing your expertise?

[Submit your application](#)

## Conferences of Interest

*Pathology & Oncology Research* is always interested in promoting relevant events for the pathology and oncology communities.

Organizing or participating in an event? Please get in touch to discuss how we may assist you in involving our community.



**frontiers** | Publishing Partnerships

POR's authors may benefit from Open Access Publishing Fees support from their institution through the Frontiers' **National** and **Institutional** Agreements. Frontiers is an award-winning Open Science platform and a leading Open Access scholarly publisher. Find out more about our Publishing Partnerships [here](#).

# Pathology & Oncology Research

Avenue du Tribunal-Fédéral 34, 1005, Lausanne

This email was sent to {{contact.EMAIL}}

You are receiving this newsletter because you are a previous author of POR.

If you do not want to receive future newsletters from the journal, you can unsubscribe by clicking the button below:

**Unsubscribe**